Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2021; 12(5): 290-308
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.290
Cellular based treatment modalities for unresectable hepatocellular carcinoma
Konstantinos Damiris, Hamza Abbad, Nikolaos Pyrsopoulos
Konstantinos Damiris, Hamza Abbad, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, United States
Nikolaos Pyrsopoulos, Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States
Author contributions: Damiris K, Abbad H, and Pyrsopoulos N equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision/editing; all authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors do not have any conflicts of interest relevant to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nikolaos Pyrsopoulos, FAASLD, AGAF, FACG, MD, PhD, Professor, Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, United States. pyrsopni@njms.rutgers.edu
Received: March 12, 2021
Peer-review started: March 12, 2021
First decision: April 6, 2021
Revised: April 19, 2021
Accepted: April 28, 2021
Article in press: April 28, 2021
Published online: May 24, 2021
Core Tip

Core Tip: Over the recent years investigation for safe and effective treatments for unresectable hepatocellular carcinoma (HCC) has shifted focus from various chemotherapeutic agents to immune based therapy. Although far from being finalized, immune cell-based therapy has shown efficacy in a variety of clinical trials, indicating possible future utilization alone or in combination for the prevention and treatment of HCC.